

List of Figures

List of Figures

- Fig. 1.** Normal artery with normal blood flow & plaque formation
- Fig. 2.** Initial stage of cholesterol deposition
- Fig. 3.** Formation of fatty streak of giant foam cells
- Fig. 4.** Expansion of foam cells
- Fig. 5.** Rupture of the atherosclerotic plaque
- Fig. 6.** General structure of lipoproteins
- Fig. 7.** Lipoprotein classification
- Fig. 8.** Structure of LDL
- Fig. 9.** Structure of HDL
- Fig. 10.** Exogenous pathway for lipoprotein metabolism
- Fig. 11.** Endogenous pathway of cholesterol
- Fig. 12.** Hardening of blood vessel leading to atherosclerosis
- Fig. 13.** Strategies for treating hyperlipidemia
- Fig. 14.** Statins - Mechanism of action
- Fig. 15.** Fibrates - Mechanism of action
- Fig. 16.** Nicotinic acid - Mechanism of action
- Fig. 17.** Bile acid resins - Mechanism of action
- Fig. 18.** Ezetimibe - Mechanism of action
- Fig. 19.** Crystal Structure of NPC1L1 Protein (PDB: 3QNT)
- Fig. 20.** 3D-Docking pose of ezetimibe with NPC1L1 Protein
- Fig. 21.** 2D- Interaction diagram of ezetimibe with NPC1L1 Protein
- Fig. 22.** 3D-Docking pose of compound **Ia** with NPC1L1 protein
- Fig. 23.** 2D-Interaction diagram of compound **Ia** with NPC1L1 protein
- Fig. 24.** 3D-Docking pose of compound **Ib** with NPC1L1 protein
- Fig. 25.** 2D-Interaction diagram of compound **Ib** with NPC1L1 protein
- Fig. 26.** 3D-Docking pose of compound **IVa** with NPC1L1 protein
- Fig. 27.** 2D-Interaction diagram of compound **IVa** with NPC1L1 protein
- Fig. 28.** 3D-Docking pose of compound **IVb** with NPC1L1 protein
- Fig. 29.** 2D-Interaction diagram of compound **IVb** with NPC1L1 protein
- Fig. 30.** 3D-Docking pose of compound **IVc** with NPC1L1 protein
- Fig. 31.** 2D-Interaction diagram of compound **IVc** with NPC1L1 protein

List of Figures

- Fig. 32.** 3D-Docking pose of compound **IVd** with NPC1L1 protein
- Fig. 33.** 2D-Interaction diagram of compound **IVd** with NPC1L1 protein
- Fig. 34.** % Reduction in total serum cholesterol levels by compounds **Vi-xx**
- Fig. 35.** % Reduction in serum triglyceride levels by compounds **Vi-xx**
- Fig. 36.** % Change in serum HDL levels by compounds **Vi-xx**
- Fig. 37.** 3D-Docking pose of ezetimibe with NPC1L1 Protein (H-bonding)
- Fig. 38.** 2D- Interaction diagram of ezetimibe with NPC1L1 Protein (H-bonding)
- Fig. 39.** 3D-Docking pose of compound **VIIIa** with NPC1L1 protein
- Fig. 40.** 2D-Interaction diagram of compound **VIIIa** with NPC1L1 protein
- Fig. 41.** % Reduction in total serum cholesterol levels by compounds **VIIIi-xvi**
- Fig. 42.** % Reduction in serum triglyceride levels by compounds **VIIIi-xvi**
- Fig. 43.** % Change in serum HDL levels by compounds **VIIIi-xvi**
- Fig. 44.** 3D-Docking pose of compound **Xa** with NPC1L1 protein
- Fig. 45.** 2D-Interaction diagram of compound **Xa** with NPC1L1 protein
- Fig. 46.** 3D-Docking pose of compound **Xb** with NPC1L1 protein
- Fig. 47.** 2D-Interaction diagram of compound **Xb** with NPC1L1 protein
- Fig. 48.** 3D-Docking pose of compound **Xc** with NPC1L1 protein
- Fig. 49.** 2D-Interaction diagram of compound **Xc** with NPC1L1 protein
- Fig. 50.** % Reduction in total serum cholesterol levels by compounds **Xi-viii**
- Fig. 51.** % Reduction in serum triglyceride levels by compounds **Xi-viii**
- Fig. 52.** % Change in serum HDL levels by compounds **Xi-viii**
- Fig. 53.** Pleiotropic effects of the PPAR family
- Fig. 54.** Crystal structure of human PPAR- γ ligand binding domain complexed with an α -aryloxyphenylacetic acid aganist – 1ZEO
- Fig. 55.** Mechanisms of ACAT1 & ACAT2
- Fig. 56.** Oxidation-reduction cycle of CoQ₁₀
- Fig. 57.** Involvement of ACL in several metabolic pathways
- Fig. 58.** Truncated human ATP citrate lyase with citrate bond– 3MWD
- Fig. 59.** Antiatherothrombotic effects of HDL
- Fig. 60.** Mechanism of action of Microsomal triglyceride transfer protein
- Fig. 61.** Role of cholesteryl ester transfer protein (CETP) inhibition in atherosclerosis

List of Figures

- Fig. 62.** Crystal structure of CETP in complex with inhibitors – 4EWS
- Fig. 63.** Conversion of pentameric form of C-reactive protein into monomeric form
- Fig. 64.** Human of C-reactive protein (CRP) complexed with phosphocholine–1B09
- Fig. 65.** Lipid oxidation in atherogenesis
- Fig. 66.** Role of DGAT in triglyceride production
- Fig. 67.** Schematic diagram for stepwise conversion of lanosterol to cholesterol
- Fig. 68.** Crystal structure of human lanosterol 14 α -demethylase (CYP51) - 3JUV
- Fig. 69.** Role of HMG synthase
- Fig. 70.** Cholesterol synthetic pathway
- Fig. 71.** Crystal structure of human squalene synthase – 1EZF
- Fig. 72.** Crystal structure of Squalene 2, 3-oxide-lanosterol cyclise - 1W6K
- Fig. 73.** Role of FXR activation in metabolism of triglyceride and cholesterol
- Fig. 74.** Crystal structure of Farnesiod X-receptor – 1OSH
- Fig. 75.** Bifunctional mechanism of SREBF-2 to maintain lipid homeostasis
- Fig. 76.** Crystal structures of SREBP-cleavage activating protein ligands – 1AM9
- Fig. 77.** Role of Apo E protein
- Fig. 78.** Role of PCSK9 in the regulation of LDL-receptor expression
- Fig. 79.** Crystal structures of PCSK9 – 2P4E
- Fig. 80.** Crystal structures of PCSK9 – 2PMW
- Fig. 81.** 3D-docking of LM-1554 into PDB structure of NPC1L1
- Fig. 82.** 3D-docking of LM-1576 into PDB structure of NPC1L1
- Fig. 83.** 3D-docking of ezetimibe into PDB structure of NPC1L1
- Fig. 84.** 3D-docking of LM-1554 into PDB structure of ACL
- Fig. 85.** 3D-docking of LM-1576 into PDB structure of ACL
- Fig. 86.** 3D-docking of ezetimibe into PDB structure of ACL
- Fig. 87.** 3D-docking of LM-1554 into PDB structure of CRP
- Fig. 88.** 3D-docking of LM-1576 into PDB structure of CRP
- Fig. 89.** 3D-docking of ezetimibe into PDB structure of CRP
- Fig. 90.** 3D-docking of LM-1554 into PDB structure of LDM
- Fig. 91.** 3D-docking of LM-1576 into PDB structure of LDM
- Fig. 92.** 3D-docking of ezetimibe into PDB structure of LDM

List of Figures

- Fig. 93.** 3D-docking of LM-1554 into PDB structure of SqS
- Fig. 94.** 3D-docking of LM-1576 into PDB structure of SqS
- Fig. 95.** 3D-docking of ezetimibe into PDB structure of SqS
- Fig. 96.** 3D-docking of LM-1554 into PDB structure of FXR
- Fig. 97.** 3D-docking of LM-1576 into PDB structure of FXR
- Fig. 98.** 3D-docking of ezetimibe into PDB structure of FXR
- Fig. 99.** Bar chart of docking scores for LM-1576, LM-1554 and co-crystallized native ligands for molecular targets
- Fig. 100.** Bar chart of docking energies for LM-1576, LM-1554 and co-crystallized native ligands for molecular targets
- Fig. 101.** Comparison of changes in lipid profiles caused by LM-1576, LM-1554 and ezetimibe in test animals during preventive study
- Fig. 102.** HPLC chromatogram after optimization of chromatographic conditions
- Fig. 103.** HPLC chromatogram of blank rabbit serum
- Fig. 104.** HPLC chromatogram of serum spiked with IS
- Fig. 105.** HPLC chromatogram of serum spiked with LM-1576 at LLOQ and IS
- Fig. 106.** Calibration curve for LM-1576
- Fig. 107.** Mean serum concentration–time profile of 5 determined by HPLC method after oral administration of 100 mg/kg LM-1576 in rabbits

Note: In Chapter-2, Figures 1–159 are numbered as per Eur. J. Med. Chem. journal.